EOD Primary Tumor

Notes

**Note 1:** When both the Federation Internationale de Gynecologie et d'Obstetrique (FIGO) stage and extension information on the primary tumor are available, use the extension information to assign the code in preference to a statement of FIGO stage. **Note 2:** Tumors in codes 100-250 with malignant ascites are coded 300. * Ascites, NOS is negative **Note 3:** Both extension to and/or discontinuous metastasis to any of the following pelvic organs are included in code 450 - Bladder and bladder serosa - Broad ligament (mesovarium) - Cul de sac - Parametrium - Pelvic peritoneum - Pelvic wall - Rectosigmoid - Rectum - Sigmoid colon - Sigmoid mesentery - Ureter, pelvic **Note 4:** Peritoneal implants may also be called seeding, salting, talcum powder appearance, or studding **Note 5:** If implants are mentioned, determine whether they are in the pelvis or in the abdomen and code appropriately. If the location of the implants is not specified, code 750. **Note 6:** Both extension to and/or discontinuous metastasis to any of the following abdominal organs by way of peritoneal seeding or implants are included in codes 600-750 - Abdominal mesentery - Diaphragm - Gallbladder - Intestine, large (except rectum) - Kidneys - Liver (peritoneal surface) - Omentum (infracolic, NOS) - Pancreas - Pericolic gutter - Peritoneum, NOS - Rectosigmoid - Sigmoid colon - Small intestine - Spleen (capsular involvement only) - Stomach - Ureters (outside pelvis) **Note 7:** Direct extension and/or metastasis to the liver or splenic parenchyma are coded in EOD Mets. **Note 8:** In some registries benign/borderline ovarian tumors are reportable by agreement. * If the tumor being reported is benign or borderline, code 999.
Code Description SS2018 T
000 In situ, intraepithelial, noninvasive, preinvasive Limited to tubal mucosa IS
100 Limited to one ovary (capsule intact) AND - No tumor on fallopian tube surface AND - No malignant cells in ascites or peritoneal washings FIGO Stage IA L
150 Limited to both ovaries (capsule(s) intact) AND - No tumor on fallopian tube surface AND - No malignant cells in ascites or peritoneal washings FIGO Stage IB L
200 Limited to one or both ovaries - WITH surgical spill FIGO Stage IC1 L
250 Limited to one or both ovaries - WITH capsule ruptured before surgery OR - WITH tumor on ovarian surface or fallopian tube surface FIGO Stage IC2 RE
300 Malignant cells in ascites or peritoneal washings FIGO Stage IC3 RE
350 Limited to one or both ovary(ies) - UNKNOWN if capsule(s) ruptured - UNKNOWN if tumor on ovarian surface or fallopian tubes - UNKNOWN if cells in ascites or peritoneal washings Localized FIGO Stage I [NOS] L
400 Extension to or implants on - Adnexa - Fallopian tube(s) - Uterus, NOS FIGO Stage IIA RE
450 Extension to or implants to other pelvic tissues Adjacent peritoneum Bladder Bladder serosa Cul de sac (rectouterine pouch) Ligament(s) (broad, ovarian, round, suspensory) Mesovarium Parametrium Pelvic wall Rectosigmoid Rectum Sigmoid colon (including sigmoid mesentery) Ureter (pelvic portion) FIGO Stage IIB RE
500 Tumor involves one or both ovaries Pelvic extension, NOS(below pelvic brim) FIGO Stage II [NOS] RE
600 Microscopic peritoneal implants beyond pelvis - Includes peritoneal surface/capsule of liver FIGO Stage IIIA RE
650 Macroscopic peritoneal implants beyond pelvis - Less than or equal to 2 cm in diameter - Includes peritoneal surface of liver FIGO Stage IIIB D
700 Macroscopic peritoneal implants beyond pelvis - Greater than 2 cm in diameter - Includes peritoneal surface of liver (liver capsule) + Includes tumor extension to liver and spleen WITHOUT parenchymal involvement of either organ FIGO Stage IIIC D
750 One or both ovaries involved WITH microscopic confirmed peritoneal metastasis outside of the pelvis Peritoneal implants, NOS Further contiguous extension FIGO Stage III [NOS] D
800 No evidence of primary tumor U
999 Unknown; extension not stated Primary tumor cannot be assessed Not documented in patient record Death Certificate Only U
(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998 (2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001. (3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL) (4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017: 3-30 (5) **Introduction to Female Reproductive Organs**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017: 631 (6) Prat, J., Olawaiye, A.B., Mutch, D.G., et al. **Ovary, Fallopian Tube, and Primary Peritoneal Carcinoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017: 681-690